Diese lokalisierte Zusammenfassung bietet einen evidenzbasierten Überblick zu diesem Thema. Der vollständige Inhalt bleibt aus redaktionellen Konsistenzgründen auf Englisch.

Orforglipron (Foundayo): First Non-Peptide Oral GLP-1, FDA Approved 2026

On April 1, 2026, the FDA approved orforglipron under the brand name Foundayo — marking it the first oral, small-molecule GLP-1 receptor agonist cleared for chronic weight management. It sits inside a peptide wiki because users searching "oral GLP-1" routinely expect a peptide, and the honest answer is that orforglipron is not a peptide at all.

Why It Shows Up in Peptide Searches

GLP-1 research started with peptide analogs (exenatide, liraglutide, semaglutide). The category is defined by receptor target, not molecular class. Orforglipron targets the same receptor as semaglutide using a completely different chemistry — a small molecule that survives the gut and doses once daily as a pill without any of the absorption workarounds oral semaglutide requires.

Correct framing:

• Semaglutide → peptide, weekly injection, or oral tablet with SNAC absorption enhancer requiring fasting.
• Orforglipron (Foundayo) → small molecule, daily oral, no absorption enhancer, no food or water timing restriction at any dose.

ATTAIN Trial Data

The pivotal ATTAIN-1 trial in obesity showed approximately 11.2% mean weight loss at 72 weeks on the approved dose, with consistent A1C reductions in the type 2 diabetes indication (ATTAIN-2). These numbers land below high-dose tirzepatide and top-dose semaglutide injectable results, but the comparison is not head-to-head and patient populations differ.

The access-and-convenience story is the primary differentiator, not peak efficacy.

Why Oral vs Injectable Matters

For the GLP-1 class specifically, delivery form drives real-world uptake more than anything else:

• Adherence improves for people with needle aversion.
• No fasting protocol unlike oral semaglutide (Rybelsus / Wegovy pill), which requires 30-minute fasting and limited water post-dose.
• Supply chain economics shift because small molecules scale more cheaply than peptide injectables at population level.
• Self-pay pricing from launch: approximately $149/month — substantially below branded injectable semaglutide.

How It Compares

• vs oral semaglutide (Wegovy pill, Dec 2025 approval): same receptor, different chemistry, different dosing logistics. Orforglipron requires no fasting window; oral semaglutide requires a 30-minute fast.
• vs injected semaglutide/tirzepatide: comparable order of magnitude in some trials but generally below injectable top-end efficacy, especially high-dose tirzepatide.
• vs retatrutide / CagriSema: different question — orforglipron is about access and form, not pushing the weight-loss efficacy ceiling.

Safety Themes

Standard GLP-1 class effects apply: GI tolerability (nausea, constipation, reduced appetite), dose-titration requirements, and the standard pancreatitis and gallbladder monitoring discussions. Gallbladder monitoring context is the same as for all GLP-1 agents.

Bottom Line

Orforglipron (Foundayo) is significant because it is the first non-peptide oral GLP-1 with FDA approval for obesity. Good coverage explains why it is not a peptide, why it competes with peptides anyway, and where it fits in a class where weekly injections have been the standard.

Educational content only. Not medical advice.